Passage Bio, Inc.
PASG
$8.49
$0.465.73%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 19.67M | 22.57M | 24.56M | 24.99M | 26.56M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 47.08M | 54.33M | 60.94M | 65.17M | 69.34M |
| Operating Income | -47.08M | -54.33M | -60.94M | -65.17M | -69.34M |
| Income Before Tax | -45.26M | -56.86M | -63.46M | -64.77M | -68.80M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -45.26 | -56.86 | -63.46 | -64.77 | -68.80 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -45.26M | -56.86M | -63.46M | -64.77M | -68.80M |
| EBIT | -47.08M | -54.33M | -60.94M | -65.17M | -69.34M |
| EBITDA | -45.81M | -52.49M | -58.46M | -62.09M | -66.17M |
| EPS Basic | -14.47 | -18.18 | -20.31 | -21.29 | -23.28 |
| Normalized Basic EPS | -8.52 | -9.88 | -11.12 | -12.26 | -13.51 |
| EPS Diluted | -14.47 | -18.18 | -20.31 | -21.29 | -23.28 |
| Normalized Diluted EPS | -8.52 | -9.88 | -11.12 | -12.26 | -13.51 |
| Average Basic Shares Outstanding | 12.55M | 12.51M | 12.49M | 12.20M | 11.85M |
| Average Diluted Shares Outstanding | 12.55M | 12.51M | 12.49M | 12.20M | 11.85M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |